Sector News

Atara hires ex-Genentech SVP to lead global R&D

May 7, 2018
Life sciences

Atara Biotherapeutics has named Dietmar Berger, M.D., Ph.D., as its global head of R&D. Berger joins after seven years at Roche’s Genentech, during which time he had a hand in the approval of drugs including PD-L1 checkpoint inhibitor Tecentriq.

Genentech hired Berger late in 2011 to oversee HER2 breast cancer programs and promoted him to the position of SVP, global clinical development for its oncology and hematology group a couple of years later. The positions gave Berger a role in many of the cancer drugs that have come down the pipeline at Roche in recent years, including Alecensa, Gazyva and Tecentriq.

Berger inherits a different set of challenges and priorities at Atara, which is closing in on a European approval of cytotoxic T lymphocyte ATA129 while putting the drug through a clutch of clinical trials. But Berger’s new employer thinks the experience he gained at Genentech will translate to Atara.

“His deep experience building high-performing teams and strategic leadership of cancer immunotherapy development will help us shape the future of our innovative T-cell immunotherapy pipeline and technology platform,” Atara CEO Isaac Ciechanover, M.D., said in a statement.

Berger joins Atara at a time when the second iteration of the biotech is reaching maturity. Atara spun out of Amgen, where Berger began his career, in 2012 and made a kidney disease candidate its top priority shortly thereafter. That plan went awry in 2015 when the kidney candidate flunked a midphase study, forcing Atara to shift gears and step up its focus on oncology.

Two years later, the switch has begun to pay off as development of ATA129 has entered the endgame. Full phase 3 readouts are still to come but Atara thinks it can package up the data generated to date to support a filing for conditional approval in Europe this year.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach